SGLT2 inhibitors: A new emerging therapeutic class in the treatment of type 2 diabetes mellitus

Journal of Clinical Pharmacology

Volumn 52, Issue 4, 2012, Pages 457-463

  Ghosh, Raktim Kumar ^a   Ghosh, Samhati Mondal ^b   Chawla, Shalini ^c   Jasdanwala, Sarfaraz Abdeli ^a  

^a MAULANA AZAD MEDICAL COLLEGE   (India)

^b LADY HARDINGE MEDICAL COLLEGE   (India)

^c UNIVERSITY OF DELHI   (India)

Author keywords

canagliflozin; dapagliflozin; new antidiabetic drug; remogliflozin; sergliflozin; SGLT2 inhibitors

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; GLIMEPIRIDE; GLUCOSE; INSULIN; METFORMIN; PHLORIZIN; REMOGLIFLOZIN ETABONATE; SERGLIFLOZIN ETABONATE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; T 1095A; UNCLASSIFIED DRUG;

ADD ON THERAPY; CONSTIPATION; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVENING DOSAGE; GENITAL TRACT INFECTION; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; KIDNEY TUBULE ABSORPTION; LOOSE FECES; MORNING DOSAGE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SINGLE DRUG DOSE; URINARY EXCRETION; URINARY FREQUENCY; URINARY TRACT INFECTION; UROGENITAL TRACT INFECTION; VULVOVAGINITIS; WEIGHT GAIN;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; GLUCOSE; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 84859030635     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270011400604     Document Type: Review

References (28)

1. Mohler ML, He Y, Wu Z, Hwang DJ, Miller DD. Recent and emerging anti-diabetes targets. Med Res Rev. 2009;29:125-195.
2. Wagman AS, Nuss JM. Current therapies and emerging targets for the treatment of diabetes. Curr Pharm Des. 2001;7:417-450. (Pubitemid 32409729)
3. Katsuno K, Fujimori Y, Ishikawa-Takemura Y, Isaji M. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol. 2009;618:98-104.
4. Wilding J. Thiazolidinediones, insulin resistance and obesity: finding a balance. Int J Clin Pract. 2006;60:1272-1280. (Pubitemid 44363665)
5. Hughes TE. Emerging therapies for metabolic diseases: the focus is on diabetes and obesity. Curr Opin Chem Biol. 2009;13:332-337.
6. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004;447:510-518. (Pubitemid 38241437)
7. Marsenic O. Glucose control bythe kidney: an emerging target in diabetes. Am J Kidney Dis. 2009;53:875-883.
8. Patel AK, Fonseca V. Turning glucosuria into atherapy: efficacy and safety with SGLT2 inhibitors. Curr Diabetes Rep. 2010;10: 101-107.
9. Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol. 2003;14:2873-2882. (Pubitemid 37305650)
10. Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract. 2008;62:1279-1284. (Pubitemid 351977622)
11. Ehrenkranz JR, Lewis NG, Kahn CR, Roth J. Phlorizin: areview. Diabetes Metab Res Rev. 2005;21:31-38.
12. Rossetti L, Smith D, Shulman GI, Papachristou D, DeFronzo RA. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest. 1987;79:1510-1515. (Pubitemid 17099657)
13. Ueta K, Ishihara T, Matsumoto Y, et al. Long-term treatment with the Nap-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki rats. Life Sci. 2005;76:2655-2668. (Pubitemid 40404055)
14. +-glucose cotransporter (SGLT) inhibitors. Bioorg Med Chem Lett. 2003;13:2269-2272.
15. Obermeier M, Yao M, Khanna A, Koplowitz B, Zhu M, Li W. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38:405-414.
16. Kipnes M. Dapagliflozin: anemerging treatment option in type 2 diabetes. Expert Opin Investig Drugs. 2009;18:327-334.
17. Fujimori Y, Katsuno K, Ojima K, et al. Sergliflozin etabonate, aselective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol. 2009; 609:148-154.
18. Minoura H, Takeshita S, Yamamoto T, et al. Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferatoractivated receptor gamma agonist, on insulin resistance in Zucker fatty rat. Eur J Pharmacol. 2005;519:182-190. (Pubitemid 43181182)
19. Fujimori Y, Katsuno K, Nakashima I, Ishikawa-Takemura Y, Fujikura H, Isaji M. Remogliflozin etabonate, in anovel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther. 2008;327:268-276.
20. Kissei Pharmaceutical Co, Ltd. Discontinuation of the development of "remogliflozin" by GlaxoSmithKline [last updated on July 3, 2009; cited September 30, 2010]. http://www.kissei.co.jp/e-contents/ press-e/2009/e20090703.html
21. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010;12:510-516.
22. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:2223-2233.
23. Ferrannini E, Jimenez Ramos S, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Care. 2010;33:2217-2224.
24. Zhang L, Feng Y, List J, Kasichayanula S, Pfister M. Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight. Diabetes Obes Metab. 2010;12:510-516.
25. Hussey EK, Clark RV, Amin DM, et al. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol. 2010;50:623-635.
26. Hussey EK, Dobbins RL, Stoltz RR, et al. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol. 2010;50:636-646.
27. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-657.
28. Arakawa K, Ishihara T, Oku A, et al. Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol. 2001;132:578-586. (Pubitemid 32142370)